Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C

Thomas F. Baumert, Christine Rösler, Michael H. Malim, Fritz von Weizsäcker – 24 August 2007 – APOBEC3G (A3G) and APOBEC3C (A3C), 2 members of the APOBEC family, are cellular cytidine deaminases displaying broad antiretroviral activity. A3G inhibits hepatitis B virus (HBV) production by interfering with HBV replication without hypermutating the majority of HBV genomes. In contrast, A3C has little effect on HBV DNA synthesis. The aim of this study was to further dissect the mechanisms by which A3G and A3C interfere with the HBV life cycle.

Dispensability and dynamics of caveolin‐1 during liver regeneration and in isolated hepatic cells

Rafael Mayoral, Amalia Fernández‐Martínez, Rosa Roy, Lisardo Boscá, Paloma Martín‐Sanz – 24 August 2007 – Caveolae participate in several cellular processes such as vesicular transport, cholesterol homeostasis, regulation of signal transduction, integrin signaling, and cell growth. The expression and functional role of caveolin (Cav), the most abundant protein of caveolae, has been reported in liver and in different hepatocyte cell lines, in human cirrhotic liver, and in hepatocellular carcinomas.

Proteomic profiling of human liver biopsies: Hepatitis C virus–induced fibrosis and mitochondrial dysfunction

Deborah L. Diamond, Jon M. Jacobs, Bryan Paeper, Sean C. Proll, Marina A. Gritsenko, Robert L. Carithers, Anne M. Larson, Matthew M. Yeh, David G. Camp, Richard D. Smith, Michael G. Katze – 24 August 2007 – Liver biopsies from hepatitis C virus (HCV)‐infected patients offer the unique opportunity to study human liver biology and disease in vivo. However, the low protein yields associated with these small samples present a significant challenge for proteomic analysis.

Mutations in the MPV17 gene are responsible for rapidly progressive liver failure in infancy

Lee‐Jun C. Wong, Nicola Brunetti‐Pierri, Qing Zhang, Nada Yazigi, Kevin E. Bove, Beverly B. Dahms, Michelle A. Puchowicz, Ignacio Gonzalez‐Gomez, Eric S. Schmitt, Cavatina K. Truong, Charles L. Hoppel, Ping‐Chieh Chou, Jing Wang, Erin E. Baldwin, Darius Adams, Nancy Leslie, Richard G. Boles, Douglas S. Kerr, William J. Craigen – 10 August 2007 – MPV17 is a mitochondrial inner membrane protein of unknown function recently recognized as responsible for a mitochondrial DNA depletion syndrome.

Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population‐based cohort study

Hannah Jackson, Masoud Solaymani‐Dodaran, Tim R. Card, Guruprasad P. Aithal, Richard Logan, Joe West – 8 August 2007 – There is debate over the mortality and malignancy risk in people with primary biliary cirrhosis (PBC) and whether this risk is reduced by use of ursodeoxycholic acid. To investigate this issue, we identified 930 people with PBC and 9,202 control subjects from the General Practice Research Database in the United Kingdom. We categorized regular ursodeoxycholic acid as treatment with 6 or more prescriptions and nonregular treatment as less than 6.

Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model

Sammy Saab, Mamie H. Dong, Tom A. Joseph, Myron J. Tong – 6 August 2007 – Hepatitis B reactivation is a major cause of morbidity and mortality in patients undergoing chemotherapy for lymphomas. These patients may experience direct liver‐related complications or reduced cancer survival because of interruptions in chemotherapy. Our aim was to compare the costs and outcomes of 2 different chronic hepatitis B management strategies.

Hepatitis C treatment in “difficult‐to‐treat” psychiatric patients with pegylated interferon‐alpha and ribavirin: Response and psychiatric side effects

Martin Schaefer, Axel Hinzpeter, Ariane Mohmand, Gesa Janssen, Maurice Pich, Markus Schwaiger, Rahul Sarkar, Astrid Friebe, Andreas Heinz, Michael Kluschke, Marlene Ziemer, Juri Gutsche, Viola Weich, Juliane Halangk, Thomas Berg – 1 August 2007 – We investigated and compared the results of treating the chronic hepatitis C (HCV) infection of different groups of psychiatric‐risk patients and controls with pegylated interferon alpha (pegIFN‐α) plus ribavirin. Seventy patients were prospectively screened for psychiatric disorders.

Subscribe to